Your browser is no longer supported. Please, upgrade your browser.
Settings
ARVN Arvinas, Inc. daily Stock Chart
ARVN [NASD]
Arvinas, Inc.
Index- P/E- EPS (ttm)-7.69 Insider Own0.50% Shs Outstand58.57M Perf Week9.47%
Market Cap1.33B Forward P/E- EPS next Y-1.93 Insider Trans- Shs Float26.00M Perf Month40.33%
Income-239.80M PEG- EPS next Q-0.46 Inst Own72.00% Short Float2.67% Perf Quarter39.38%
Sales14.30M P/S92.77 EPS this Y-736.70% Inst Trans0.03% Short Ratio5.14 Perf Half Y53.14%
Book/sh4.38 P/B5.17 EPS next Y-4.30% ROA-184.30% Target Price20.33 Perf Year-
Cash/sh3.21 P/C7.06 EPS next 5Y- ROE219.30% 52W Range10.19 - 25.61 Perf YTD76.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.56% Beta-
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin- 52W Low122.28% ATR1.26
Employees83 Current Ratio8.50 Sales Q/Q30.80% Oper. Margin- RSI (14)64.62 Volatility4.95% 7.15%
OptionableNo Debt/Eq0.02 EPS Q/Q-72.70% Profit Margin- Rel Volume0.42 Prev Close22.70
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume135.07K Price22.65
Recom- SMA2017.78% SMA5019.91% SMA20031.98% Volume56,529 Change-0.22%
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated Goldman Neutral $17
Oct-22-18Initiated Citigroup Buy $21
Apr-02-19 07:00AM  Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer GlobeNewswire +8.33%
Mar-26-19 07:00AM  Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-25-19 07:00AM  Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC Protein Degrader, ARV-110 GlobeNewswire
Mar-16-19 09:16AM  Did Arvinas Holding Company, LLC (NASDAQ:ARVN) Insiders Buy Up More Shares? Simply Wall St.
Feb-07-19 04:30PM  Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium GlobeNewswire
Feb-01-19 12:08PM  Protein Degradation: Finally, A Way To Treat 'Undruggable' Diseases? Investor's Business Daily
Jan-04-19 05:00PM  Arvinas Receives Authorization to Proceed for its IND Application for PROTAC Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire +6.35%
Dec-07-18 07:00PM  Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire +5.07%
Nov-20-18 06:00AM  Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Oct-23-18 07:30AM  Arvinas to Present at Two Protein Degradation Conferences GlobeNewswire
Oct-03-18 08:15PM  Arvinas Inc (ARVN) President and CEO John G Houston Bought $480,000 of Shares GuruFocus.com +5.67%
Sep-27-18 10:42AM  Arvin's stock soars in its public debut, after upsized IPO priced at top of expected range MarketWatch
06:49AM  [$$] Biotech Arvinas Prices Upsized IPO at High End of Range The Wall Street Journal
Sep-26-18 08:06PM  Arvinas Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.